文献速递头颈部肿瘤放疗

头颈鳞癌复发与高危治疗体积的关系

Recurrence of head and neck squamous cell carcinoma in relation to high-risk treatment volume.
PubMed 文献 · Clin Transl Radiat Oncol · 2021-02-03

31个复发病灶中45%为野内复发、16%为边缘遗漏、39%为真遗漏;p16阳性与阴性患者均在高危治疗体积内复发。作者认为p16阳性肿瘤也需在广泛开展降强度放化疗前表征放疗抵抗生物标志物,并需减少p16阴性病例的真遗漏和边缘遗漏。

要点

  • 31个复发病灶中45%为野内、16%为边缘遗漏、39%为真遗漏。
  • p16阳性患者有4个野内、2个边缘、1个真遗漏复发。
  • p16阴性患者有10个野内、3个边缘、11个真遗漏复发。

核心结论

  • p16阳性和阴性头颈鳞癌均在高危治疗体积内复发,尽管前者通常被认为放射敏感性高。
  • 在广泛开展降强度放化疗方案前,应在p16阳性肿瘤中表征预测放疗抵抗的生物标志物。
  • 尽管采用多模态影像靶区勾画,p16阴性病例的真遗漏和边缘遗漏仍需减少。

研究设计与样本

  • 回顾性研究,复习2010-2015年确诊的508例头颈鳞癌患者病历。
  • 筛选出在混合正电子发射断层扫描(PET)/计算机断层扫描(CT)和/或磁共振成像(MRI)上出现局部和/或区域复发、且p16状态已知的患者进行详细分析。
  • 将复发肿瘤复制到计划CT上,并使用剂量体积直方图确定复发肿瘤体积的受照剂量。

主要发现

  • 在18例p16阴性和7例p16阳性患者中检测到31个局部和/或区域复发病灶。
  • 31个复发病灶中14个(45%)为野内复发,5个(16%)为边缘遗漏,12个(39%)为真遗漏。
  • p16阳性患者有4个野内、2个边缘、1个真遗漏复发;p16阴性患者有10个野内、3个边缘、11个真遗漏复发。

临床怎么用

  • 对p16阳性头颈鳞癌患者,即使采用标准光子放疗,也应警惕高危治疗体积内复发。
  • 在降强度放化疗方案广泛实施前,需在p16阳性肿瘤中寻找预测放疗抵抗的生物标志物。
  • 对p16阴性病例,需关注如何减少真遗漏和边缘遗漏。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Locoregional recurrence remains a major cause of failure in head and neck squamous cell carcinoma (HNSCC). Human papilloma virus (HPV)-associated HNSCCs generally have a good prognosis but may recur even after standard photon radiotherapy (RT). Another incentive in observing patterns of recurrence is increased use of highly conformal techniques such as proton therapy. We therefore studied geographic distribution of recurrent tumors in relation to the high-risk treatment volume in a cohort of patients with HNSCC receiving combined modality therapy. METHODS: Medical records of 508 patients diagnosed with HNSCC in 2010-2015 were reviewed. We identified a subgroup that had local and/or regional recurrence at hybrid positron emission tomography (PET)/computed tomography (CT) and/or magnetic resonance imaging (MRI). We adapted p16 as a surrogate marker for HPV-positivity and only patients with known p16 status were eligible for a detailed analysis where recurrent tumor was copied on the planning CT and the dose received by the recurrent tumor volume was determined using dose-volume histograms. RESULTS: Twenty-five patients who had received either cisplatin (n = 23) or cetuximab-enhanced (n = 2) RT were identified. 31 locoregional recurrent tumors were detected among 18 p16 negative and 7 p16 positive patients. Of recurrent tumors 14 (45%) were classified as in-field, 5 (16%) as marginal miss, and 12 (39%) as true miss. p16 positive patients had 4 in-field, 2 marginal, and 1 true miss. By contrast, p16 negative patients had 10 in-field, 3 marginal, and 11 true miss recurrences. CONCLUSIONS: Both p16 positive and negative HNSCC recur in high-risk treatment volume despite the common view of high radiosensitivity of the former. Biomarkers predicting radioresistance should be characterized in p16 positive tumors before widely embarking on de-escalated CRT protocols. Another concern is how to decrease the number of true or marginal misses in p16 negative cases despite multimodality imaging-based target delineation.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Nissi L, Suilamo S, Kytö E, et al. Recurrence of head and neck squamous cell carcinoma in relation to high-risk treatment volume. Clin Transl Radiat Oncol. 2021. PMID: 33665383. doi:10.1016/j.ctro.2021.01.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。